Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2004-03-31
2008-09-30
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S265100, C544S244000, C544S280000
Reexamination Certificate
active
07429574
ABSTRACT:
Novel deazapurines are disclosed which are useful for the treatment of adenosine receptor stimulated diseases.
REFERENCES:
patent: 3037980 (1962-06-01), Hitchings et al.
patent: 3910913 (1975-10-01), Kim et al.
patent: 5208240 (1993-05-01), Peet et al.
patent: 5296484 (1994-03-01), Coghlan et al.
patent: 5409930 (1995-04-01), Spada et al.
patent: 5516894 (1996-05-01), Reppert
patent: 5580870 (1996-12-01), Barker et al.
patent: 5639913 (1997-06-01), Lidor et al.
patent: 5646130 (1997-07-01), Shi
patent: 5646156 (1997-07-01), Jacobson et al.
patent: 5681941 (1997-10-01), Cook et al.
patent: 5710158 (1998-01-01), Myers et al.
patent: 5714493 (1998-02-01), Myers et al.
patent: 5721237 (1998-02-01), Myers et al.
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5780450 (1998-07-01), Shade
patent: 5780481 (1998-07-01), Jacobson et al.
patent: 5834609 (1998-11-01), Horne et al.
patent: 5877180 (1999-03-01), Linden et al.
patent: 5877218 (1999-03-01), Herzig et al.
patent: 5877221 (1999-03-01), Cohen et al.
patent: 5880159 (1999-03-01), Herzig et al.
patent: 5889026 (1999-03-01), Alanine et al.
patent: 5914349 (1999-06-01), Cohen et al.
patent: 5935964 (1999-08-01), Baraldi et al.
patent: 5962458 (1999-10-01), Lohmann et al.
patent: 5994408 (1999-11-01), Cohen et al.
patent: 6103899 (2000-08-01), Horne et al.
patent: 6117878 (2000-09-01), Linden
patent: 6465456 (2002-10-01), Springer et al.
patent: 6664252 (2003-12-01), Castelhano et al.
patent: 6673802 (2004-01-01), Castelhano et al.
patent: 6680322 (2004-01-01), Castelhano et al.
patent: 6680324 (2004-01-01), Castelhano et al.
patent: 6686366 (2004-02-01), Castelhano et al.
patent: 6916804 (2005-07-01), Castelhano et al.
patent: 7202252 (2007-04-01), Wilson et al.
patent: 2002/0028782 (2002-03-01), Castelhano et al.
patent: 2002/0094974 (2002-07-01), Castelhano et al.
patent: 2003/0139427 (2003-07-01), Castelhano et al.
patent: 2003/0229067 (2003-12-01), Castelhano et al.
patent: 2004/0082598 (2004-04-01), Castelhano et al.
patent: 2004/0082599 (2004-04-01), Castelhano et al.
patent: 2005/0119271 (2005-06-01), Castelhano et al.
patent: 2008/0070936 (2008-03-01), Castelhano et al.
patent: 0322242 (1989-06-01), None
patent: 0514540 (1992-11-01), None
patent: 0682027 (1995-11-01), None
patent: 0729758 (1996-04-01), None
patent: 0729758 (1996-09-01), None
patent: 0773023 (1997-05-01), None
patent: 1246623 (2006-08-01), None
patent: 0915303 (1963-01-01), None
patent: 3145287 (1993-05-01), None
patent: 0157280 (1986-02-01), None
patent: 9291089 (1999-05-01), None
patent: WO 9320078 (1993-10-01), None
patent: WO 9705138 (1994-02-01), None
patent: WO 9413676 (1994-06-01), None
patent: WO 9417090 (1994-08-01), None
patent: WO 9419349 (1994-09-01), None
patent: WO 9424136 (1994-10-01), None
patent: WO 9511681 (1995-05-01), None
patent: WO 9518617 (1995-07-01), None
patent: WO 9519774 (1995-07-01), None
patent: WO 9519970 (1995-07-01), None
patent: WO 9520597 (1995-08-01), None
patent: WO 9619478 (1996-06-01), None
patent: WO 9702266 (1997-01-01), None
patent: WO 9733879 (1997-09-01), None
patent: 9747601 (1997-12-01), None
patent: WO 9807726 (1998-02-01), None
patent: WO 9808382 (1998-03-01), None
patent: WO 9822465 (1998-05-01), None
patent: WO 9829397 (1998-07-01), None
patent: WO 9857651 (1998-12-01), None
patent: WO 9906053 (1999-02-01), None
patent: WO 9908460 (1999-02-01), None
patent: WO 9933815 (1999-07-01), None
patent: WO 9942093 (1999-08-01), None
patent: 9964407 (1999-12-01), None
patent: WO 9962518 (1999-12-01), None
patent: WO 0003741 (2000-01-01), None
patent: 2001039777 (2001-06-01), None
patent: 2002057267 (2002-07-01), None
patent: 2003048120 (2003-06-01), None
patent: 2003053361 (2003-07-01), None
patent: 2003053366 (2003-07-01), None
Luo Yan; Joachim C Burbiel; Astrid Maaβ; Christa E Müller, Expert Opinion on Emerging Drugs 2003, vol. 8, No. 2, pp. 537-576.
Pier Giovanni Baraldi; Allan R Moorman; Mojgan Aghazadeh Tabrizi; MariaGiovanna Pavani; Romeo Romagnoli, Expert Opinion on Therapeutic Patents, 2004, vol. 14, No. 1, pp. 71-79.
P.G. Baraldi; B. Cacciari; R. Romagnoli; G. Spalluto, Expert Opinion on Therapeutic Patents, 1999, vol. 9, No. 5, pp. 515-527.
Avila, M.Y. (2001) AI-A2a and A3-Subtype Adenosine receptors Modulate Intraocular Pressure in the Mouse J. of Pharmacol. 241-24.
Knutsen, L.J.S. et al. (2001) Curr. Opin. Invest. Drugs 2(5):668-673.
Phillis, J.W. (1995) The EfFects of Selective A1 and A2a Adenosine Receptor Antagonists on Cerebral Ischemic • Brain Research 705:79-84.
Szkotak, A.J. e˜al. 2001) “Regulation of K+ Current in Human Airway Epithelial Cells by Exogenous and Autocrine Adenosine” Am. J. Physiol. Cell Physiol. 281 :C 1991-C2000.
Welch, W.J. (2002) “Adenosine Type 1 Receptor Antagonists in Fluid Retaining Disorders” Expert Opin.i 11(11): 1553-1562.
Marx, D. et al., Drug News Perspect. (2001), 14(2): 89-100.
Phillis, J.W. Brain Research (1995). 705:79-84.
Yan's Expert Opinion on Emerging Drugs, 2003.
Baraldi (Expert Opinion on Therapeutic Patents, 2004).
Baraldi (Expert Opinion on Therapeutic Patents, 1999).
U.S. Appl. No. 10/497,451, filed May 27, 2004, Castelhano et al.
Abbracchio M., et al., (1997) “Modulation of Apoptosis by Nervous System: a Possible Role for the A, Receptor”,Ann. NY, Acad. Sci., 825: 11-22.
Abbracchio M., et al., (1999) “Brain Adenosine Receptors as Targets for Therapeutic Intervention in Neurodegenerative Diseases”,Ann. NY. Acad. Sci, 890: 79-92.
Banker, G.S. et al.,Modern Pharmaceutics, 3rded., Marcel Dekker, New York, 1996, p. 596 (Exhibit 5).
Baraldi P., et al., (2000) “New potent and selective human adenosine A3receptor antagonists”,Tips, 21: 456-459.
U.S. Appl. No. 09/454,074, filed Dec. 2, 1999, Castelhano, et al.
Barrett, R.J. (1996) “Realizing the Potential of Adenosine-Receptor-Based Therapeutics”Proc. West. Pharmacol. Soc, 39: 61-66 (Exhibit 2).
Blazynski C., (1990) “Discrete Distributions of Adenosine Receptors in Mammalian Retina”,Journal of Neurochemistry, 53: 648-655.
Braas K.M., et al. (1987) “Endogenous adenosine and adenosine receptors localized to ganglion cells of the retina”,Proceedings of the National Academy of Science, 84: 3906-3910.
Bradford M. M., (1976) “A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding”,Anal. Biochem., 72: 248.
Brand A., et al., (2001) “Adenosine A1 and A3 receptors mediate inhibition of synaptic transmission in rat cortical neurons”,Neuropharmacology, 40: 85-95.
Broach, J. R., et al., (1983) “Vectors for high level, inducible expression of cloned genes in yeast”, Inouye (ed).,Experimental Manipulation of Gene Expression. Academic Press, New York, 83-117.
Bundy, G.L. et al. (1995) “Synthesis of Novel 2,4-Diaminopyrrolo-[2,3-d-d]pyrimidines with Antioxidant, Neuroprotective, and Antiasthma Activity”J. Med. Chem.38:4161-4163.
Casavola V., et al., (1998) “Adenosine A3 receptor activation increases cystolic calcium concentration via calcium influx in A6 cells”,Drug Development Research, 43 (1): 62.
Chen, Y. L., et al., (1997) “Synthesis and Oral Efficacy of a 4-(Butylethylamino)pyrrolo[2,3-d]pyramidine: A Centrally Active Corticotropin-Releasing Factor, Receptor Antagonist”,J. Med. Chem., 40: 1749-1754.
Cheng, Y. and Prusoff, W. H. (1973) “Relationship Between The Inhibition Constant (κi) And The Concentration Of Inhibitor Which Causes 50 Per Cent Inhibition (l50) Of An Enzymatic Reaction”,Biochem. Pharmacol., 22: 3099-3109.
Christianson, T. W. et al., (1992) “Multifunctional yeast high-copy-number shuttle vectors”,Gene, 110: 119-122.
DeNinno, M.P. inAnnual Reports in Medicinal Chemistry, vol. 33, (Academic Press: San Diego, 1998), pp. 111-120.
Dooley, M.J. et al., “Theoretical Structure-Activity Studies of Adenosine A1 Ligands: Requirements for Receptor Affinity”Bioorg. Med. Chem. (1996), 4
Castelhano Arlindo L.
McKibben Bryan
Witter David J.
Cooper & Dunham LLP
Moore Susanna
OSI Pharmaceuticals, Inc.
White John P.
Wilson James O.
LandOfFree
4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3987177